

1 **Title:** Seroprevalence of Enteric Fever in Juba, South Sudan

2

3 **Authors:**

4 Kristen Aiemjoy, John Rumunu, Juma John Hassen, Kirsten E. Wiens, Denise Garrett, Polina
5 Kamenskaya, Jason B. Harris, Andrew S. Azman, Peter Teunis, Jessica Seidman, Joseph F.
6 Wamala, Jason R. Andrews, Richelle C. Charles

7

8

9 **Affiliations:**

10 Division of Epidemiology, Department of Public Health Sciences, UC Davis School of
11 Medicine, Davis, CA, USA (K Aiemjoy);
12 Republic of South Sudan Ministry of Health, Juba, South Sudan (J. Rumunu);
13 World Health Organization, Juba (J.J. Hassen, J.F. Wamala);
14 Sabin Vaccine Institute, Washington DC, USA (D. Garrett, J. Siedman)
15 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (K.E. Wiens,
16 A.S. Azman)
17 Emory University, Atlanta, Georgia, USA (P Teunis)
18 Division of Infectious Diseases and Geographic Medicine, Stanford University School of
19 Medicine, Stanford, CA, USA (J.R. Andrews)
20 Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA (P.
21 Kamenskaya, R.C. Charles, J Harris)

22

23 **Funding:** This work was supported by the World Health Organization’s (WHO) Unity Studies, a
24 global seroepidemiologic standardization initiative, with funding provided by the COVID-19
25 Solidarity Response. This study was also supported by The Bill and Melinda Gates Foundation
26 (INV-000572) and the US National Institutes of Health (R01AI134814).

27

28

29 **ABSTRACT**

30 We apply a new serosurveillance tool to estimate typhoidal *Salmonella* burden from dried blood
31 spots in Juba, South Sudan, finding a seroprevalence rate of 35 per 100 person-years and
32 cumulative incidence of 78% over four years.

33

34

35 **INTRODUCTION**

36 Enteric fever, a systemic bacterial infection caused by *Salmonella enterica* serovars Typhi and
37 Paratyphi, causes substantial illness and mortality globally (1). However, estimating the
38 population-level burden of infection is challenging. The reference standard for both diagnosis

39 and surveillance, blood culture, requires microbiological laboratory facilities that are not
40 available in many low-and-middle income countries.

41
42 Juba, the capital city of South Sudan, experiences a high burden of enteric infections such as
43 cholera and hepatitis E virus (2,3). While enteric fever is a frequently diagnosed etiology of acute
44 fever, there are no laboratories with blood culture capacity to confirm the diagnosis. Similarly,
45 with no blood culture facilities, the population-level burden of enteric fever is unknown.

46
47 Hemolysin E (HlyE), a pore-forming toxin, has proven to be an accurate serologic marker for
48 diagnosing typhoidal salmonella (4–9). New serologic tools have recently been developed to
49 measure population-level enteric fever incidence from cross-sectional serosurveys using anti-IgG
50 and IgA responses HlyE (10). Here, we apply these tools to generate population-level enteric
51 fever incidence estimates in Juba, South Sudan, using banked dried blood spots collected for a
52 SARS-CoV-2 serosurvey (11).

53

54 **METHODS**

55 This study utilizes dried blood spots (DBS) collected from participants of a representative
56 SARS-CoV-2 serosurvey in Juba, South Sudan enrolled between August 7th and September 20nd,
57 2020 (11). Two-stage cluster sampling was used to randomly select households from predefined
58 enumeration units within six administrative divisions within and surrounding Juba. All
59 individuals ≥ 1 year of age and residing for ≥ 1 week within the sampled household were eligible
60 to participate. Capillary blood was collected onto Whatman 903 Protein Saver cards, air dried
61 and transported at ambient temperature to Massachusetts General Hospital where they were
62 stored at 4°C. We tested all banked samples collected from participants under age 25 and a
63 random sample of participants 25 and older. The study protocol was approved by ethical review
64 boards with the South Sudan Ministry of Health and Mass General Hospital.

65

66 We used kinetic enzyme-linked immunosorbent assays to quantify antibody levels present in
67 eluted DBS as previously described (5,6) . We submerged two 6 mm² punches from the DBS in
68 133 μ L of PBS-0.05% Tween 20r overnight at 4°C with gentle agitation, and recovered eluate
69 after centrifugation. The eluate was stored frozen at -20 C until testing.

70
71 We used the antibody dynamics modeled from a longitudinal cohort of 1410 blood culture-
72 confirmed enteric fever cases (10) to estimate enteric fever incidence as described in (12–14). In
73 brief, we created a likelihood function for the observed cross-sectional population data based on
74 antibody dynamics following blood-culture confirmed infection. We generated joint incidence
75 estimates by combining the likelihood for HlyE IgA and IgG for each age stratum (0-4yr, 5 -
76 15yr, ≥ 16 yr) using age-specific antibody dynamics. This method incorporates heterogeneity in
77 antibody responses and explicitly accounts for measurement error and biologic noise as detailed
78 in (10). We used the same method to generate individual-level incidence estimates based on
79 quantitative HlyE IgA and IgG responses and used the exponential probability distribution to
80 calculate the two-year and four-year cumulative incidence. We then fit age-dependent curves to
81 using generalized additive models (15) with a cubic spline for age and simultaneous confidence
82 intervals using a parametric bootstrap of the variance-covariance matrix of the fitted model
83 parameters (16). We compared our results to the seroprevalence derived from a mean plus three
84 standard deviation cutoff using North American control population of 1) 48 children aged 1-5
85 years who had first degree relatives with celiac disease, enrolled nationally and 2) 31 healthy
86 controls, children and young adults aged 2-18 years, enrolled at Massachusetts General Hospital
87 (17). Code and de-identified data are available on ([link ToBeAdded_github_repo](#)).

88 89 **RESULTS**

90 2214 individuals were enrolled and provided blood samples, 1840 had complete interview data
91 and 1290 were randomly selected for testing (11). The median age of tested participants was 17
92 years old (interquartile range (IQR) 10-24), and 63.5% (819/1290) were female (Table 1).

93
94 Median HlyE IgG (10.4, IQR 6.1 – 12.7) and IgA (3.5, IQR 2.3 – 5.2) responses were elevated
95 well above a North American pediatric control population (IgG: 0.16, IQR 0.07 – 0.35; IgA: 0.3,
96 IQR 0.001 – 0.92) and were comparable to responses observed among blood-culture confirmed
97 enteric fever cases 8-12 months after symptom onset (IgG: 12, IQR 5.9– 24; IgA: 4.4, IQR 2.2 –
98 9.4) (10) (Figure 1).

99

100 The age-specific enteric fever incidence estimates per 100 person-years ranged from 27.8 (95%
101 confidence interval (CI): 26.4 – 32.4) among children 10 to 14 years old to 51.6 (95% CI: 46. –
102 70.7 among children 1 to 3 years old (Figure 2). The overall incidence rate was 35.0 (95% CI
103 32.4-37.9). The cumulative incidence over two years was 52.7% (IQR 37.2-67.2) and over 4
104 years was 77.6% (IQR 60.6 - 49.3). Using a cutoff derived from a North American pediatric
105 control population, 99.8% (1288/1290) of the population were seropositive using HlyE IgG and
106 65.2% (318/488) were positive using HlyE IgA (Supplemental Figure 1).

107

108

109 **DISCUSSION**

110 Here we apply a new serosurveillance tool to estimate the population-level incidence of enteric
111 fever in Juba, South Sudan. Using banked DBS collected for a SARS-CoV-2 serosurvey, we
112 rapidly estimated the burden of typhoidal *Salmonella* in a region with no blood culture
113 surveillance and no population-level enteric fever incidence estimates. We estimated a high
114 incidence rate of 35.0 infections per 100 person-years, with over 75% of the sampled population
115 infected in the prior 4 years.

116

117 The analytic approach is an improvement over cutoff based methods in that we can combine
118 information from both HlyE IgA and IgG responses to generate a consensus incidence estimate,
119 while accounting for heterogeneity in antibody responses, measurement error and biologic noise.
120 While the cutoff-based method yielded a seroprevalence of nearly 100% for HlyE IgG, we
121 generated cumulative incidence estimates over a precise time window and could identify
122 populations with recent and later infections.

123

124 There are limitations to this study which should be considered when interpreting the results.
125 First, only 1840 samples of the 2214 enrolled had linked age data. Second, internally-displaced
126 person camps were not included in the serosurvey. As displaced persons have been identified as
127 high-risk populations for enteric infections, it would be valuable to include them in future enteric
128 fever surveillance studies to determine if this population is at higher or equivalent risk (2).
129 Finally, we used longitudinal antibody kinetics estimates from enteric fever cases in Bangladesh,
130 Pakistan, Nepal and Ghana to estimate incidence in South Sudan. While we did not observe overt

131 differences in the kinetics of antibody responses across countries (10), it may still be possible
132 that the decay rate among enteric fever cases in Juba is different because of the high force of
133 infection and differences in exposure to other infections.

134
135 Our results suggest a high burden of enteric fever in Juba, South Sudan warranting urgent public
136 health and research attention. The seroincidence tool we use can be applied to other regions
137 lacking blood culture surveillance to generate rapid enteric fever incidence estimates, providing
138 the high-resolution data critically needed to inform typhoid conjugate vaccine introduction.

139
140

141 TABLES

142 **Table 1: Summary of population**

143

	Overall (N=1290)
Sex	
Female	819 (63.5%)
Male	471 (36.5%)
Age, in years	
Median (IQR)	17 (10-24)
Age category, in years	
1-3	41 (3.2%)
4-6	118 (9.1%)
7-9	134 (10.4%)
10-14	259 (20.1%)
15-24	423 (32.8%)
25-34	167 (12.9%)
35-44	62 (4.8%)
45+	86 (6.7%)

144

145

146

147 **Table 2: Age-dependent incidence rates and cumulative incidence**

Age, in years	Incidence rate per 100 person-years (95% CI)	Two-year Cumulative Incidence (IQR)	Four-year Cumulative Incidence (IQR)
1-3	51.6 (46.3-70.7)	57.9% (50.1-78.4)	82.2% (75.1-95.4)
4-6	35.2 (32.5-44.3)	59.1% (37.0-70.1)	83.3% (60.3-91.0)
7-9	33.2 (31.0-40.5)	52.5% (42.6-62.0)	77.4% (67.0-85.6)
10-14	27.8 (26.4-32.4)	48.1% (34.6-61.6)	73.1% (57.2-85.2)
15-24	31.6 (27.5-47.2)	47.5% (33.6-65.3)	72.5% (55.9-87.9)
25-34	33.7 (31.3-42.1)	56.3% (40.2-69.8)	80.9% (64.2-90.9)
35-44	45.8 (40.4-65.9)	61.3% (54.6-71.9)	85.0% (79.4-92.1)
45+	39.0 (35.1-53.0)	56.5% (45.1-72.2)	81.1% (69.9-92.3)
Overall	35.0 (32.4-37.9)	52.7% (37.2-67.3)	77.6% (60.6-89.3)

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169 **REFERENCES**

170

171 1. GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and
172 paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017.
173 *Lancet Infect Dis.* 2019 Apr;19(4):369–81.

174 2. Azman AS, Bouhenia M, Iyer AS, Rumunu J, Laku RL, Wamala JF, et al. High Hepatitis E
175 Seroprevalence Among Displaced Persons in South Sudan. *Am J Trop Med Hyg.* 2017 Jun
176 7;96(6):1296–301.

177 3. Abubakar A, Bwire G, Azman AS, Bouhenia M, Deng LL, Wamala JF, et al. Cholera Epidemic
178 in South Sudan and Uganda and Need for International Collaboration in Cholera Control.
179 *Emerg Infect Dis.* 2018 May;24(5):883–7.

180 4. Kumar S, Nodoushani A, Khanam F, DeCruz AT, Lambotte P, Scott R, et al. Evaluation of a
181 Rapid Point-of-Care Multiplex Immunochromatographic Assay for the Diagnosis of Enteric
182 Fever. *mSphere.* 2020 Jun 10;5(3).

183 5. Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al. Identification of
184 Immunogenic *Salmonella enterica* Serotype Typhi Antigens Expressed in Chronic Biliary
185 Carriers of *S. Typhi* in Kathmandu, Nepal. *PLOS Neglected Tropical Diseases.* 2013 Aug
186 1;7(8):e2335.

187 6. Andrews JR, Khanam F, Rahman N, Hossain M, Bogoch II, Vaidya K, et al. Plasma
188 Immunoglobulin A Responses Against 2 *Salmonella Typhi* Antigens Identify Patients With
189 Typhoid Fever. *Clinical Infectious Diseases.* 2019 Mar 5;68(6):949–55.

190 7. McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, Sabo A, et al. Comparison
191 of genome degradation in Paratyphi A and Typhi, human-restricted serovars of *Salmonella*
192 *enterica* that cause typhoid. *Nat Genet.* 2004 Dec;36(12):1268–74.

193 8. Charles RC, Liang L, Khanam F, Sayeed MA, Hung C, Leung DT, et al. Immunoproteomic
194 Analysis of Antibody in Lymphocyte Supernatant in Patients with Typhoid Fever in
195 Bangladesh. *Clin Vaccine Immunol.* 2014 Mar;21(3):280–5.

196 9. Charles RC, Sheikh A, Krastins B, Harris JB, Bhuiyan MS, LaRocque RC, et al.
197 Characterization of Anti-*Salmonella enterica* Serotype Typhi Antibody Responses in
198 Bacteremic Bangladeshi Patients by an Immunoaffinity Proteomics-Based Technology. *Clin*
199 *Vaccine Immunol.* 2010 Aug;17(8):1188–95.

200 10. Aiemjoy K, Seidman JC, Saha S, Munira SJ, Sajib MSI, Sium SMA, et al. Estimating typhoid
201 incidence from community-based serosurveys: A multicohort study in Bangladesh, Nepal,
202 Pakistan and Ghana [Internet]. 2021 Nov [cited 2021 Nov 29] p. 2021.10.20.21265277.
203 Available from: <https://www.medrxiv.org/content/10.1101/2021.10.20.21265277v2>

- 204 11. Wiens KE, Mawien PN, Rumunu J, Slater D, Jones FK, Moheed S, et al. Seroprevalence of
205 Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020 -
206 Volume 27, Number 6—June 2021 - Emerging Infectious Diseases journal - CDC. [cited
207 2021 Dec 3]; Available from: https://wwwnc.cdc.gov/eid/article/27/6/21-0568_article
- 208 12. de Graaf WF, Kretzschmar MEE, Teunis PFM, Diekmann O. A two-phase within-host model
209 for immune response and its application to serological profiles of pertussis. *Epidemics*.
210 2014 Dec;9:1–7.
- 211 13. Teunis PFM, van Eijkeren JCH, de Graaf WF, Marinović AB, Kretzschmar MEE. Linking the
212 seroresponse to infection to within-host heterogeneity in antibody production. *Epidemics*.
213 2016 Sep;16:33–9.
- 214 14. Teunis PFM, van Eijkeren JCH. Estimation of seroconversion rates for infectious diseases:
215 Effects of age and noise. *Stat Med*. 2020 Sep 20;39(21):2799–814.
- 216 15. Wood SN. *Generalized additive models: an introduction with R*. Chapman and Hall/CRC;
217 2006.
- 218 16. Marra G, Wood SN. Coverage properties of confidence intervals for generalized additive
219 model components. *Scandinavian Journal of Statistics*. 2012;39(1):53–74.
- 220 17. Leonard MM, Camhi S, Huedo-Medina TB, Fasano A. Celiac Disease Genomic,
221 Environmental, Microbiome, and Metabolomic (CDGEMM) Study Design: Approach to the
222 Future of Personalized Prevention of Celiac Disease. *Nutrients*. 2015 Nov 11;7(11):9325–
223 36.

224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240

241 **FIGURE LEGENDS:**



242

243 **Figure 1: Age-dependent anti-hemolysin E (HlyE) IgA (top) and IgG (bottom) responses in**
244 **Juba population sample compared to blood culture confirmed cases between 8 and 12**
245 **months from fever onset and North American controls.** (A) Cross-sectional antibody
246 responses to HlyE IgA and IgG according to age in years measured from a serosurvey of 1290
247 individuals in Juba, South Sudan collected between August 7th and September 2nd, 2020. Each
248 point is an individual sample. (B) Density of antibody responses among 1410 blood-culture
249 confirmed enteric fever cases in Bangladesh, Nepal, Pakistan and Ghana between 8 and 12
250 months after symptom onset as reported in (10) and anegative control population of 1) 48
251 children aged 1-5 years who had first degree relatives with celiac disease, enrolled nationally and
252 2) 31 healthy controls, children and young adults aged 2-18 years, enrolled at Massachusetts
253 General Hospital (17). The dashed blue line across all three panels represents the mean plus three
254 standard deviations of HlyE IgA and IgG values observed in the pediatric control population.


255 **Figure 2: Estimated sero-incidence of typhoidal Salmonella by age group in Juba, South**
256 **Sudan.** (A) Sero-incidence per age-group with 95% credible intervals. (B & C) Individually-
257 predicted incidence estimates (points) and the smoothed cumulative incidence over two years (B)
258 and four-years (C).

259 **Supplemental Figure 1: Age dependent seroprevalence curves using negative control cutoff.**
260 Each point is an individual classified into positive or negative based on a cutoff derived from a
261 North American control population for HlyE IgA (left) and HlyE IgG (right). The purple line is
262 the age-dependent sero-prevalence curve fit using generalized additive models.




(A)



(B)



medRxiv preprint doi: <https://doi.org/10.1101/2022.02.28.22271472>; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

(A)**(B)****(C)**

HlyE IgA

HlyE IgG

